Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis

被引:7
|
作者
Poonam, Jain P. [1 ]
Mayur, Parihar [3 ]
Rayaz, Ahmed [2 ]
Aby, Abraham [2 ]
Auro, Vishwabandya [2 ]
Biju, George [2 ]
Vikram, Mathews [2 ]
Alok, Srivastava [2 ]
Vivi, Srivastava M. [1 ]
机构
[1] Christian Med Coll & Hosp, Cytogenet Unit, Vellore 632004, Tamil Nadu, India
[2] Christian Med Coll & Hosp, Dept Hematol, Vellore 632004, Tamil Nadu, India
[3] Tata Med Ctr, Dept Cytogenet, Kolkata, W Bengal, India
关键词
Chronic myelogenous leukemia; BCR/ABL1; fusion; atypical FISH signals; CHRONIC-MYELOID-LEUKEMIA; D-FISH PATTERNS; DERIVATIVE CHROMOSOME-9; VARIANT TRANSLOCATIONS; CYTOGENETIC RESPONSE; GENE REARRANGEMENTS; PERIPHERAL-BLOOD; CLONAL EVOLUTION; CML; DELETIONS;
D O I
10.4103/0377-4929.101742
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Chronic myelogenous leukemia (CML) is characterised by the t(9;22)(q34;q11.2) which results in the formation of the BCR/ABL1 fusion gene. Occasionally, the t(9;22) may be associated with submicroscopic deletions of chromosomes 9 and/or 22 which appear to be associated with a worse prognosis. Three or four-way variant t(9;22) may also occur. All these changes as well as gain of the Philadelphia chromosome which represents disease progression can be detected by fluorescence in situ hybridization (FISH) analysis. FISH analysis at presentation is used to determine the number of cells with BCR/ABL1 fusion and establish whether the patterns are typical or atypical. Response to therapy can then be monitored by serial testing. Patients and Methods: The study group consisted of all patients diagnosed or suspected to have CML who had interphase FISH analysis at presentation on peripheral blood/bone marrow using a commercially available BCR/ABL1 dual colour, dual fusion probe. The study was performed at a tertiary hospital in India between 2004 and 2010. Results: There were 1076 diagnostic samples which were positive for BCR/ABL1 fusion. Typical dual fusion signals (two fusions, one red and one green, 2F1R1G) were seen in 801 cases (74 %). Atypical signal patterns were seen in 275 cases (26%). These were: 1F1R2G (4%), 1F2R1G (2.5%) and 1F1R1G (11%) representing deletions of the derivative 9 involving chromosome 9 sequences, chromosome 22 sequences, or both respectively; 3F1R1G (6.5%) usually representing gain of an additional Philadelphia chromosome and 1F2R2G (1%) representing a three-or four-way variant translocation. More than one signal pattern was seen in 1%. Conclusions: Our findings were similar to the literature with respect to the distribution of signal patterns except that we had a lower number of patients with variant translocations. While each signal pattern is typically associated with a particular abnormality, there can be more than one explanation for each pattern. Hence, metaphase FISH analysis is the "gold standard" for the interpretation of signal patterns.
引用
下载
收藏
页码:347 / 351
页数:5
相关论文
共 50 条
  • [41] Detection of the BCR ABL1 Translocation in Patients with Chronic Myelogenous Leukemia (CML) by DNA based Looped Ligation Assay (LOLA)
    Harada, S.
    Silzle, E.
    Gocke, C. D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (06): : 868 - 868
  • [42] The BCR/ABL-extra signal fluorescence in situ hybridization system reliably detects deletions upstream of the ABL locus:: implications for reporting of results and followup of chronic myelogenous leukemia patients
    Müller, C
    Hennig, E
    Franke, C
    Krahl, R
    Leiblein, S
    Niederwieser, D
    Deininger, MWN
    CANCER GENETICS AND CYTOGENETICS, 2002, 136 (02) : 149 - 150
  • [43] ETV6/ABL1 FUSION IN CHRONIC MYELOID LEUKEMIA
    Gancheva, K.
    Brazma, D.
    Howard-Reeves, J.
    Mazzullo, H.
    Zareian, N.
    Partheniou, P.
    Kotzampaltiris, P.
    Grace, C.
    Virchis, A.
    Nacheva, E.
    HAEMATOLOGICA, 2012, 97 : 72 - 72
  • [44] FUSED TRANSCRIPT OF ABL AND BCR GENES IN CHRONIC MYELOGENOUS LEUKEMIA
    SHTIVELMAN, E
    LIFSHITZ, B
    GALE, RP
    CANAANI, E
    NATURE, 1985, 315 (6020) : 550 - 554
  • [45] BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia
    Gruenebach, Frank
    Mirakaj, Valbona
    Mirakaj, Valdete
    Mueller, Martin R.
    Bruemmendorf, Tim
    Brossart, Peter
    CANCER RESEARCH, 2006, 66 (11) : 5892 - 5900
  • [46] BCR-ABL RNA IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
    SHTIVELMAN, E
    GALE, RP
    DREAZEN, O
    BERREBI, A
    ZAIZOV, R
    KUBONISHI, I
    MIYOSHI, I
    CANAANI, E
    BLOOD, 1987, 69 (03) : 971 - 973
  • [47] CHRONIC MYELOGENOUS LEUKEMIA BCR/ABL POSITIVE COMPLICATING A PREGNANCY
    Tello, E. Juarez Ramirez
    Sultan, A.
    Khan, S.
    Tijani, L.
    Nugent, K.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (02) : 475 - 475
  • [48] Distribution and analysis of chromosomal breakpoints within ABL1 in Chronic Myelogenous Leukemia (CML)
    Knoll, Joan H.
    Miralles, Mauricio E.
    Newkirk, Heather L.
    Flejter, Wendy
    Rogan, Peter K.
    CANCER RESEARCH, 2006, 66 (08)
  • [49] Fluorescent In Situ Hybridization Analysis of Philadelphia Chromosome-Negative Chronic Myeloid Leukemia with the bcr/abl Fusion Gene
    Fumihiko Monma
    Kazuhiro Nishii
    Shunji Yamamori
    Noboru Hosokai
    Takahiro Nakazaki
    Felipe Lorenzo V
    Eiji Usui
    Miho Sakakura
    Hiroyuki Miyashita
    Atsushi Fujieda
    Kohshi Ohishi
    Naoyuki Katayama
    Hiroshi Shiku
    International Journal of Hematology, 2004, 80 : 155 - 158
  • [50] PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA WITH DELETED FUSION OF BCR AND ABL GENES
    OHYASHIKI, K
    OHYASHIKI, JH
    IWABUCHI, H
    TAUCHI, T
    IWABUCHI, A
    TOYAMA, K
    JAPANESE JOURNAL OF CANCER RESEARCH, 1990, 81 (01): : 35 - 42